185 related articles for article (PubMed ID: 7890372)
1. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres.
Shahin R; Leef M; Eldridge J; Hudson M; Gilley R
Infect Immun; 1995 Apr; 63(4):1195-200. PubMed ID: 7890372
[TBL] [Abstract][Full Text] [Related]
2. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells.
Conway MA; Madrigal-Estebas L; McClean S; Brayden DJ; Mills KH
Vaccine; 2001 Feb; 19(15-16):1940-50. PubMed ID: 11228364
[TBL] [Abstract][Full Text] [Related]
3. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.
Jones DH; McBride BW; Thornton C; O'Hagan DT; Robinson A; Farrar GH
Infect Immun; 1996 Feb; 64(2):489-94. PubMed ID: 8550197
[TBL] [Abstract][Full Text] [Related]
4. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.
Eldridge JH; Staas JK; Meulbroek JA; Tice TR; Gilley RM
Infect Immun; 1991 Sep; 59(9):2978-86. PubMed ID: 1879922
[TBL] [Abstract][Full Text] [Related]
5. Intranasal immunization of BALB/c mice with enterotoxigenic Escherichia coli colonization factor CS6 encapsulated in biodegradable poly(DL-lactide-co-glycolide) microspheres.
Byrd W; Cassels FJ
Vaccine; 2006 Feb; 24(9):1359-66. PubMed ID: 16233937
[TBL] [Abstract][Full Text] [Related]
6. Poly(lactide-co-glycolide) microencapsulation of vaccine antigens.
Jones DH; McBride BW; Farrar GH
J Biotechnol; 1996 Jan; 44(1-3):29-36. PubMed ID: 8717383
[TBL] [Abstract][Full Text] [Related]
7. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.
Macdonald-Fyall J; Xing D; Corbel M; Baillie S; Parton R; Coote J
Vaccine; 2004 Oct; 22(31-32):4270-81. PubMed ID: 15474718
[TBL] [Abstract][Full Text] [Related]
8. Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model.
Kimura A; Mountzouros KT; Relman DA; Falkow S; Cowell JL
Infect Immun; 1990 Jan; 58(1):7-16. PubMed ID: 2294058
[TBL] [Abstract][Full Text] [Related]
9. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres.
Allaoui-Attarki K; Pecquet S; Fattal E; Trollé S; Chachaty E; Couvreur P; Andremont A
Infect Immun; 1997 Mar; 65(3):853-7. PubMed ID: 9038287
[TBL] [Abstract][Full Text] [Related]
10. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
[TBL] [Abstract][Full Text] [Related]
11. Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres.
Yan C; Rill WL; Malli R; Hewetson J; Naseem H; Tammariello R; Kende M
Vaccine; 1996 Aug; 14(11):1031-8. PubMed ID: 8879098
[TBL] [Abstract][Full Text] [Related]
12. Protection against intranasal infection of mice with Bordetella pertussis.
Robinson A; Ashworth LA; Baskerville A; Irons LI
Dev Biol Stand; 1985; 61():165-72. PubMed ID: 2872102
[TBL] [Abstract][Full Text] [Related]
13. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA.
Roberts M; Cropley I; Chatfield S; Dougan G
Vaccine; 1993; 11(8):866-72. PubMed ID: 8356847
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice.
Orr B; Douce G; Baillie S; Parton R; Coote J
Vaccine; 2007 Jan; 25(1):64-71. PubMed ID: 16916566
[TBL] [Abstract][Full Text] [Related]
15. PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model.
Li P; Asokanathan C; Liu F; Khaing KK; Kmiec D; Wei X; Song B; Xing D; Kong D
Int J Pharm; 2016 Nov; 513(1-2):183-190. PubMed ID: 27586408
[TBL] [Abstract][Full Text] [Related]
16. Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin.
Cahill ES; O'Hagan DT; Illum L; Redhead K
FEMS Microbiol Lett; 1993 Mar; 107(2-3):211-6. PubMed ID: 8472903
[TBL] [Abstract][Full Text] [Related]
17. Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection.
Denoël P; Poolman J; Carletti G; Veitch K
Vaccine; 2002 Jun; 20(19-20):2551-5. PubMed ID: 12057612
[TBL] [Abstract][Full Text] [Related]
18. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
20. Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein.
Carbonetti NH; Artamonova GV; Andreasen C; Dudley E; Mays RM; Worthington ZE
Infect Immun; 2004 Jun; 72(6):3350-8. PubMed ID: 15155640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
